A randomized trial of 5-fluorouracil, leucovorin, cisplatin and epirubicin (PELF) versus 5-fluorouracil, leucovorin and etoposide (ELF) given as adjuvant chemotherapy to patients with resected advanced gastric adenocarcinomas.
Abstract
PURPOSE: To compare the efficacy and toxicity between 2 regimens [5 fluorouracil (5-FU), leucovorin and etoposide (ELF) and 5-FU, leucovorin, cisplatin and epirubicin (PELF)] administered as postoperative adjuvant chemotherapy to patients with completely resected advanced gastric cancer. PATIENTS AND METHODS: Between 1998-2002, 78 patients with advanced gastric cancer were randomly assigned to receive 6 cycles of adjuvant ELF or PELF combination chemotherapy after complete surgical tumor resection. Endpoints were disease-free survival (DFS), overall survival and treatment toxicity. RESULTS: ELF was administered to 37 and PELF to 41 patients. Median overall survival was 12.3 months in the ELF group and 17.2 months in the PELF group (p=0.01), respectively. For the ELF group the median DFS was 17 weeks (range 7-160 weeks), while for the PELF group it was 35 weeks (range 12-172 weeks) (p=0.0004). Two-year overall survival was 8% (3 patients) in the ELF group and 24% (10 patients) in the PELF group (p=0.03). Grade 2 hematologic toxicity occurred in 21% (8 patients) in the ELF group and in 22% (9 patients) in the PELF group (p=0.5) and grade 3 in 29% (11 patients) in the ELF group and in 24% (10 patients) in the PELF group (p=0.2). Grade 2 non-hematologic toxicity was seen in 8% (3 patients) in the ELF group and in 17% (7 patients) in the PELF group (p=0.2). Grade 3 non-hematologic toxicity occurred in 29% (11 patients) in the ELF group and in 26.8% (11 patients in the PELF group) (p=0.2). CONCLUSION: PELF combination chemotherapy resulted in DFS and overall survival advantage compared with ELF. No significant differences in hematologic or non-hematologic toxicities between the two groups were registered. PELF is superior to ELF and represents a valid option for the treatment of gastric cancer.
AI evidence extraction
Main findings
In 78 randomized patients (ELF n=37; PELF n=41), median overall survival was 12.3 months with ELF vs 17.2 months with PELF (p=0.01). Median DFS was 17 weeks with ELF vs 35 weeks with PELF (p=0.0004), and 2-year overall survival was 8% vs 24% (p=0.03). No statistically significant differences in reported grade 2/3 hematologic or non-hematologic toxicities were observed between groups.
Outcomes measured
- Disease-free survival (DFS)
- Overall survival
- Treatment toxicity (hematologic and non-hematologic; grade 2 and grade 3)
View raw extracted JSON
{
"study_type": "randomized_trial",
"exposure": {
"band": null,
"source": null,
"frequency_mhz": null,
"sar_wkg": null,
"duration": null
},
"population": "Patients with completely resected advanced gastric adenocarcinoma receiving postoperative adjuvant chemotherapy",
"sample_size": 78,
"outcomes": [
"Disease-free survival (DFS)",
"Overall survival",
"Treatment toxicity (hematologic and non-hematologic; grade 2 and grade 3)"
],
"main_findings": "In 78 randomized patients (ELF n=37; PELF n=41), median overall survival was 12.3 months with ELF vs 17.2 months with PELF (p=0.01). Median DFS was 17 weeks with ELF vs 35 weeks with PELF (p=0.0004), and 2-year overall survival was 8% vs 24% (p=0.03). No statistically significant differences in reported grade 2/3 hematologic or non-hematologic toxicities were observed between groups.",
"effect_direction": "benefit",
"limitations": [],
"evidence_strength": "high",
"confidence": 0.7399999999999999911182158029987476766109466552734375,
"peer_reviewed_likely": "yes",
"keywords": [
"gastric adenocarcinoma",
"adjuvant chemotherapy",
"randomized trial",
"5-fluorouracil",
"leucovorin",
"cisplatin",
"epirubicin",
"etoposide",
"overall survival",
"disease-free survival",
"toxicity"
],
"suggested_hubs": []
}
AI can be wrong. Always verify against the paper.
Comments
Log in to comment.
No comments yet.